IsoTherapeutics
Private Company
Funding information not available
Overview
IsoTherapeutics Group, LLC is a commercial-stage radiopharmaceutical services company founded in 2004 and based in Angleton, Texas. It operates as a contract development and manufacturing organization (CDMO) offering expertise in chelation, conjugation, radiolabeling, analytical services, and cGMP production for the radiopharmaceutical industry. The company's acquisition by Telix Pharmaceuticals integrates its specialized capabilities into Telix's global radiopharmaceutical platform, expanding Telix's U.S. manufacturing footprint and vertical integration strategy. IsoTherapeutics' business is built on over 100 patents and decades of combined scientific experience in radiochemistry.
Technology Platform
Specialized radiopharmaceutical CDMO platform offering chelation, conjugation, radiolabeling, kit development, analytical services, and cGMP manufacturing for targeted radionuclide therapies and diagnostics.
Opportunities
Risk Factors
Competitive Landscape
IsoTherapeutics competes with other specialized radiopharmaceutical CDMOs (e.g., ITM, NorthStar Medical Radioisotopes services) and the internal manufacturing arms of large radiopharma companies. Its differentiation lies in its deep patent portfolio, end-to-end service offering, and strategic position as part of Telix's integrated platform.